Cartesian Therapeutics Inc. (RNAC) — Cash Flow-to-Debt Ratio
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of $-15.60 Million could theoretically repay 0% of its total liabilities ($408.52 Million) in one year. See Cartesian Therapeutics Inc. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cartesian Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Cartesian Therapeutics Inc. across 11 annual periods. Also explore RNAC shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cartesian Therapeutics Inc. (2014–2024)
Year-by-year debt coverage analysis for Cartesian Therapeutics Inc.. For market capitalisation and broader financial context, see RNAC market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | $-23.67 Million | $441.82 Million | ▲ +21.9% |
| 2023 | -0.07x | $-51.16 Million | $745.23 Million | ▲ +84.4% |
| 2022 | -0.44x | $-31.63 Million | $72.06 Million | ▲ +0.1% |
| 2021 | -0.44x | $-60.38 Million | $137.36 Million | ▼ -331.2% |
| 2020 | 0.19x | $34.88 Million | $183.44 Million | ▲ +133.7% |
| 2019 | -0.56x | $-51.44 Million | $91.17 Million | ▲ +52.4% |
| 2018 | -1.19x | $-59.16 Million | $49.90 Million | ▼ -12.3% |
| 2017 | -1.06x | $-52.04 Million | $49.29 Million | ▼ -84.2% |
| 2016 | -0.57x | $-19.68 Million | $34.34 Million | ▼ -306.5% |
| 2015 | -0.14x | $-22.46 Million | $159.32 Million | ▼ -22.2% |
| 2014 | -0.12x | $-12.69 Million | $109.98 Million | — |